Drugs / W_ova1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04163094 | Nov 2019 → Jun 2023 | ovarian cancer | University Medical Center Groningen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | W_ova1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163094 ↗ |
| Modality | Messenger RNA (mRNA) | “Liposome Formulated mRNA Vaccine” NCT04163094 ↗ |
| Route | Intravenous | “Vaccines will be administered by means of intravenous injection.” NCT04163094 ↗ |